OTR-AC

OTR-AC is an acetate-ester prodrug of ostarine (enobosarm, MK-2866) — a non-steroidal selective androgen receptor modulator. The ester itself is pharmacologically inert; it serves as a lipophilic delivery vehicle that is cleaved by serum and tissue esterases to liberate free ostarine, which then drives all downstream activity at the androgen receptor (AR). Every mechanism below describes what the parent compound does once esterase cleavage has occurred.

Tissue-Selective Androgen Receptor Agonism#

The active aryl-propanamide binds the AR ligand-binding domain and induces a conformational change that recruits a muscle-and-bone-biased set of coregulators rather than the full agonist signal that endogenous testosterone or DHT would trigger across all AR-expressing tissue. The result is full agonist activity in skeletal muscle and bone, with only weak partial agonism in prostate, sebaceous, and hair-follicle tissue.

"Enobosarm showed tissue-selective agonist activities, functioning as a full agonist in muscle/bone while having only weak partial agonist activity in prostate." — Hwang DJ et al., J Med Chem (2019)

Practically, this is the entire reason the SARM class exists: the user gets the anabolic transcriptional program in muscle without the prostatic, sebaceous, and follicular load that comes with testosterone or trenbolone. Hair-line and sebum response are notably tamer than on AAS — a major reason the looksmaxxing audience tolerates ostarine where they wouldn't tolerate equivalent-anabolism oral AAS.

Anabolic Transcription and Lean Mass Accretion#

Once the AR is activated in myocytes, the receptor translocates to the nucleus and drives transcription of myogenic genes — IGF-1 upregulation, MyoD activation, myostatin downregulation, and increased nitrogen retention. This is the same transcriptional program AAS engage; the SARM simply runs it in muscle tissue selectively. Phase II data on the parent compound at a 3 mg/day clinical dose — roughly a fifth of a recreational dose — confirmed the program runs as expected in humans.

"At the 3-mg dose, statistically significant increases in total lean body mass and improvements in physical function, as measured by the stair climb power test, were observed compared with placebo." — Dalton JT et al., J Cachexia Sarcopenia Muscle (2011)

The same effect was reproduced in catabolic populations — cancer cachexia patients, where muscle preservation in a deficit is the hardest possible test of an anabolic agent:

"Treatment with enobosarm was associated with statistically significant increases in total lean body mass and improved stair climb power versus placebo in patients with cancer-associated muscle wasting." — Dobs AS et al., Lancet Oncol (2013)

This cachexia evidence is why OTR-AC and parent ostarine are the default community choice for muscle-sparing in aggressive cuts — the underlying ligand has the strongest published anti-catabolic signal of any SARM.

Esterase-Mediated Prodrug Release#

The acetate group is what differentiates OTR-AC from raw ostarine. Esterification is the same medicinal-chemistry strategy used to extend the duration of testosterone (enanthate, cypionate) and trenbolone (acetate, enanthate) — the lipophilic ester partitions into tissue and is gradually hydrolysed by ubiquitous esterases, liberating free drug at a metered rate. Applied to an orally-active SARM, the practical consequence is a flatter, longer serum curve rather than the sharper Tmax peak seen with parent ostarine.

"The longer-lasting acetate ester means that OTR-AC is preferred by users looking for a once-daily protocol and steadier blood levels, though direct clinical data on the ester is not available." — Predator Nutrition editorial (2023)

Worth saying plainly: no peer-reviewed PK on the ester has been published. The 36–48 h functional half-life is a community estimate inferred from subjective duration of effect, not a measured terminal half-life. The pharmacology is plausible — esterification reliably extends half-life across drug classes — but the "10× more potent" vendor marketing has no clinical backing. The community read is that OTR-AC behaves like ostarine dosed at roughly half the mg, with smoother daily kinetics and a slightly longer suppression tail.

HPTA Suppression Pathway#

The same AR agonism that drives muscle accretion also signals at the hypothalamus and pituitary, blunting GnRH, LH, and FSH release and suppressing endogenous testosterone production. This is dose-dependent and present even at the 3 mg clinical dose, which is why the community standard at recreational doses (10–20 mg/day OTR-AC) is a mini-PCT after any cycle ≥8 weeks. The extended ester profile means suppression resolves on a slightly longer timeline than parent ostarine — recovery windows reported as 1–2 weeks longer, which is the operational reason PCT and post-cycle bloodwork are timed at week 4–6 post-cessation rather than week 2–3.

Connective Tissue and Collagen Signalling#

AR is expressed in tendon, ligament, and bone tissue, and ostarine has the most consistent anecdotal joint-relief signal in the SARM class. The mechanism is the same AR-driven transcriptional program — upregulation of collagen synthesis and connective-tissue remodelling — running in tenocytes and osteoblasts rather than just myocytes. This is the rationale for the between-cycle bridge protocol: lifters running heavy orals reach for OTR-AC at 12.5–15 mg during off-cycle windows specifically for elbow, shoulder, and knee tendinopathy, not just for the recomp signal.

Common (most users)#

• HPTA suppression — the defining side effect. Even 3mg/day of parent ostarine reduces total testosterone, LH, FSH, and SHBG in healthy subjects (Dalton et al. 2011). At 10–15mg OTR-AC the suppression is meaningful and the extended ester half-life pushes recovery 1–2 weeks longer than parent ostarine. Mitigation: keep cycles at or under 8 weeks, run a proper mini-PCT, and confirm recovery with post-cycle bloods.
• SHBG drop — consistent and dose-dependent. Often shows up as elevated libido and stronger pumps mid-cycle, then unmasked low free-test symptoms post-cycle if PCT is skipped. Mitigation: bloodwork at week 4 and post-cycle.
• Mild lipid shift — HDL trends down, LDL trends up. Less aggressive than oral 17-aa AAS but real. Mitigation: citrus bergamot 1000mg/day, 2–4g EPA/DHA, cardio 3x/week. Pre/post lipid panel is non-negotiable.
• Transient lethargy or "flat" feeling in week 5–8 — usually the suppression catching up. Mitigation: confirm with bloods rather than chasing dose increases.
• Aggressive pumps and calf/lower-back cramping — welcome at 10mg, painful past 15mg. Mitigation: 3–5g taurine daily, electrolytes, water intake 3L+.
• Mild headache and nausea in the first week — documented in the phase II trials (Dalton et al. 2011). Usually self-limiting. Mitigation: dose with a fat-containing meal.

Uncommon (dose-dependent or individual)#

• Insomnia — community-reported past 15mg/day on OTR-AC specifically (r/sarmssourcetalk). Mitigation: split AM/PM with the larger fraction in the morning, or back off to 12.5mg.
• Mild ALT/AST elevation — usually 1.5–2x ULN, resolving post-cycle. Mitigation: mid-cycle CMP at week 4. If ALT trends past 3x ULN, the protocol ends.
• Deeper HDL suppression in lipid-sensitive individuals — some users see HDL drop 30–40% on 15–20mg protocols. Mitigation: dose reduction, extended cardio block, niacin if tolerated.
• Mood flatness or low motivation late in cycle — the suppression signature. Bloodwork distinguishes this from training fatigue.
• Estradiol creep — ostarine can be weakly aromatised through AR-mediated feedback effects on residual testosterone, and SHBG suppression unmasks free E2. Mitigation: include estradiol on the panel, not just total test.

When ALT clears 3x ULN, HDL drops >40%, or resting BP climbs past 140/90, the protocol is stopped — not adjusted.

Rare but serious#

• Cholestatic liver injury — case reports exist in the SARM literature, ostarine included, at recreational doses. Warning signs: jaundice, dark urine, pale stools, right-upper-quadrant pain, pruritus. Discontinuation is immediate.
• Failure of HPTA recovery — rare at ≤15mg/8 weeks, more plausible at 20mg+ run back-to-back without off-time. Warning sign: week-6-post-cycle bloods showing total test still <300 ng/dL with low LH. Action: extended SERM protocol under physician oversight.
• Significant blood pressure elevation — uncommon at OTR-AC monotherapy doses, more likely when stacked with harsh orals. Warning sign: resting BP creeping past 140/90.
• Severe dyslipidemia in genetically predisposed subjects — apoB and Lp(a) can move in users with familial hypercholesterolemia background. An advanced lipid panel pre-cycle catches this before it matters.

Hard contraindications#

• Active or recent androgen-sensitive malignancy — the propanamide scaffold has dual SARM/SARD pharmacology depending on tissue context (Hwang et al. 2018). Not a compound to introduce into a patient with prostate, breast, or other AR-driven malignancy history.
• Pre-existing cholestatic liver disease or baseline LFT elevation — no second-line liver compound layered on a compromised baseline.
• Untreated hypertension or untreated dyslipidemia — fix the baseline first; SARMs amplify both.
• Pregnancy or near-term plans for conception — HPTA suppression, unknown fetal androgenic exposure, and unresolved post-cycle recovery windows.
• Stacking with oral 17α-alkylated AAS without mid-cycle CMP and lipid panels — the combined hepatic and lipid burden is where the case-report-grade injuries come from.
• Back-to-back cycles without an off-period equal to cycle length — suppression compounds, recovery doesn't.

Gender-specific and PCT considerations#

Ostarine is the SARM with the cleanest female-use signal in the class, owing to its weak partial-agonist activity in androgenic tissue. Female protocols cap at 5mg/day OTR-AC for 6–8 weeks. Virilization risk (voice deepening, clitoral hypertrophy, hirsutism) is lower than LGD-4033, RAD-140, or S23 but is not zero — early voice changes are the canary, and the protocol ends at first sign.

For male users, PCT is required for any cycle ≥8 weeks at ≥15mg/day, and is community-standard even for shorter protocols at lower doses. Standard mini-PCT: enclomiphene 12.5mg/day or clomid 25mg EOD for 3–4 weeks, starting 3–5 days after the final dose (the ester's extended half-life means waiting through the washout). Confirmatory bloodwork at week 4–6 post-PCT: total test, free test, LH, FSH, SHBG, estradiol. Recovery to baseline is the standard — not "back in normal range," but back to individual pre-cycle numbers.

Anyone running OTR-AC without pre-cycle, mid-cycle, and post-PCT bloods is flying blind on a compound with no published human PK. The bloodwork is the protocol.